Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Current Report on Form 8-K on November 13, 2023. The filing serves to announce the Company's results of operations for the fiscal quarter ended September 30, 2023. The Company's common stock trades on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were announced via a press release, which is attached as Exhibit 99.1, but the financial data itself is not embedded in the text of this 8-K.
Material Changes
No material changes or comparative financial data are detailed within the body of this filing. The report references the press release for the specific operational results for the quarter ended September 30, 2023.
Guidance, Outlook, and Risks
This filing does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies. It strictly references the attached press release for the announcement of the quarterly results. The filing includes standard legal disclaimers stating that the information furnished in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 13, 2023) for actual revenue, net loss, and cash position figures.
- Verify the Company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm the status of any debt obligations or financing activities not detailed in this summary.